Fate Therapeutics (FATE) Tops Q2 EPS by 7c
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.